Exclusive: Intas set to buy Teva’s UK & Ireland assets for $775 million Industry-The Economic Times — October 5, 2016 comments off With the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK generics market.
With the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK generics market.